CommercialPrior AuthMedium impact
Nonmyeloablative Allogeneic Transplants of Hematopoietic Stem-Cells for Treatment of Malignancy
Blue Cross & Blue Shield of Mississippi·MS · Oncology, Hematology·Medical Policy
We identified it
Jun 20, 2026
Summary
Blue Cross & Blue Shield of Mississippi updated their policy on nonmyeloablative allogeneic stem cell transplants for cancer treatment. The policy requires prior authorization through Case Management for all covered transplant procedures and evaluations, and specifies that the procedure is only medically necessary for patients who would otherwise meet criteria for high-dose chemotherapy and allogeneic stem cell transplantation.
Action Required
Immediately: Billing team must ensure prior authorization through Case Management is obtained from BCBS Mississippi before scheduling or billing for any nonmyeloablative allogeneic stem cell transplant procedures or evaluations. Update billing system to flag these procedures for mandatory prior auth. Claims will be denied without prior authorization.